Takafumi Hiro Selected Research

pitavastatin (itavastatin)

10/2022	Small Dense Low-Density Lipoprotein Cholesterol and Cardiovascular Risk in Statin-Treated Patients with Coronary Artery Disease.
10/2021	Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy.
3/2018	Rationale and Design of Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) Trial.
1/2018	High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
2/2016	Stabilization of atherosclerotic plaque by pitavastatin in Watanabe heritable hyperlipidemic rabbits: A serial tissue-characterizing intravascular ultrasound study.
3/2015	Remodeling pattern is related to the degree of coronary plaque regression induced by pitavastatin: a sub-analysis of the TOGETHAR trial with intravascular ultrasound and coronary angioscopy.
1/2013	Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study.
1/2012	Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study.
12/2011	Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial.
10/2010	More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takafumi Hiro Research Topics

Disease

20	Coronary Artery Disease (Coronary Atherosclerosis) 10/2022 - 11/2006
16	Acute Coronary Syndrome 01/2020 - 12/2006
10	Atherosclerotic Plaque (Atheroma) 01/2021 - 06/2005
6	Stable Angina 10/2021 - 02/2008
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 09/2010
6	Atherosclerosis 10/2017 - 02/2007
5	Myocardial Infarction 01/2018 - 01/2014
4	Thrombosis (Thrombus) 01/2015 - 09/2011
3	Hypercholesterolemia 01/2019 - 02/2007
3	Diabetes Mellitus 01/2016 - 06/2010
2	Neointima 01/2022 - 12/2019
2	Rupture 01/2018 - 10/2014
2	Pathologic Constriction (Stenosis) 01/2018 - 10/2005
2	Myocardial Ischemia (Ischemic Heart Diseases) 04/2016 - 02/2016
2	Reperfusion Injury 04/2016 - 02/2016
2	ST Elevation Myocardial Infarction 04/2016 - 02/2016
2	Aneurysm (Aneurysms) 01/2016 - 02/2008
2	Heart Failure 01/2016 - 01/2002
2	Coronary Disease (Coronary Heart Disease) 07/2012 - 02/2007
1	Atrial Fibrillation 01/2022
1	Prodromal Symptoms 01/2020
1	Syncope (Fainting) 01/2020
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Dyslipidemias (Dyslipidemia) 06/2018
1	Coronary Occlusion 01/2018
1	Hemorrhage 04/2016
1	Infarction (Infarctions) 04/2016
1	Myocardial Reperfusion Injury 04/2016
1	Hyperemia 06/2013
1	Hyperglycemia 06/2013
1	Left Ventricular Outflow Obstruction 06/2013
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2012
1	Ventricular Tachycardia 01/2011
1	Ventricular Premature Complexes (Premature Ventricular Contraction) 01/2011
1	Coronary Aneurysm (Aneurysm, Coronary) 02/2008

Drug/Important Bio-Agent (IBA)

21	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2022 - 12/2006
14	pitavastatin (itavastatin)FDA Link 10/2022 - 12/2006
14	LipidsIBA 10/2022 - 06/2005
11	Atorvastatin (Lipitor)FDA Link 01/2019 - 12/2006
7	LDL CholesterolIBA 10/2022 - 02/2007
7	Rosuvastatin Calcium (Crestor)FDA Link 01/2019 - 02/2007
5	oxidized low density lipoproteinIBA 01/2019 - 10/2012
3	Phenobarbital (Luminal)FDA Link 01/2020 - 10/2005
2	HDL CholesterolIBA 01/2022 - 09/2010
2	alirocumabIBA 01/2019 - 01/2018
2	Fluspirilene (Imap)IBA 10/2017 - 01/2016
2	Sodium-Hydrogen ExchangersIBA 04/2016 - 02/2016
2	3- guanidinocarbonyl- 2- methyl- 6,7,8,9- tetrahydro- 5H- cyclohepta(b)pyridine- 9- ylmethyl sulfuric acidIBA 04/2016 - 02/2016
2	MetalsIBA 10/2014 - 09/2011
1	AnticoagulantsIBA 01/2022
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2022
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022
1	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2021
1	Prasugrel Hydrochloride FDA Link 01/2020
1	Clopidogrel (Plavix)FDA Link 01/2020
1	2',4'-dichlorobenzamil amiloride (DCBA)IBA 12/2019
1	Pharmaceutical PreparationsIBA 12/2019
1	saxagliptin FDA Link 01/2019
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2019
1	CholesterolIBA 01/2018
1	Ezetimibe (Zetia)FDA Link 10/2017
1	Glucagon-Like Peptide-1 ReceptorIBA 10/2017
1	lixisenatideIBA 10/2017
1	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2017
1	LDL Receptors (LDL Receptor)IBA 04/2016
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2016
1	Oxygen (Dioxygen)IBA 01/2016
1	Tolvaptan FDA Link 01/2016
1	DiureticsIBA 01/2016
1	Glycoside Hydrolase InhibitorsIBA 06/2013
1	miglitol (Glyset)FDA Link 06/2013
1	Dobutamine FDA LinkGeneric 06/2013
1	Advanced Glycation End ProductsIBA 01/2013
1	Matrix Metalloproteinases (MMPs)IBA 01/2013
1	CreatinineIBA 10/2012
1	Glucose (Dextrose)FDA LinkGeneric 07/2012
1	Amlodipine (Norvasc)FDA LinkGeneric 01/2011
1	Polyvinyl Chloride (PVC)IBA 01/2011
1	azelnidipineIBA 01/2011
1	omega-Chloroacetophenone (Mace)IBA 09/2010
1	Triglycerides (Triacylglycerol)IBA 09/2010
1	AdiponectinIBA 09/2010
1	remnant-like particle cholesterolIBA 06/2010
1	Sirolimus (Rapamycin)FDA Link 02/2008
1	Polytetrafluoroethylene (Teflon)FDA Link 02/2008
1	Oxidoreductases (Dehydrogenase)IBA 02/2007
1	Coenzyme A (CoA)IBA 02/2007
1	Formaldehyde (Formol)FDA Link 06/2005

Therapy/Procedure

22	Therapeutics 10/2022 - 07/2009
8	Stents 12/2019 - 05/2002
7	Percutaneous Coronary Intervention 06/2021 - 02/2008
4	Drug-Eluting Stents 01/2022 - 09/2011
1	Aftercare (After-Treatment) 12/2019
1	Intravenous Infusions 04/2016
1	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2016
1	Sutures (Suture) 01/2016
1	Perioperative Period 01/2015
1	Secondary Prevention 12/2014
1	Drug Therapy (Chemotherapy) 01/2013
1	Catheters 06/2005